Latest News

Savolitinib plus osimertinib met PFS and OS end points vs chemotherapy in the phase 3 SAFFRON trial of EGFR-mutated, MET-driven NSCLC.

FDA reviews OST-HER2 survival data for potential accelerated approval for preventing recurrent metastatic osteosarcoma after lung surgery.

A retrospective cohort study of metastatic castration-sensitive prostate cancer found no difference between the ARPI agents overall, but a signal for survival benefit in those aged 75 or older.

A guide to breast cancer biomarker testing, from ER/PR and HER2-low status to PIK3CA, AKT1, and ESR1 mutations across diagnosis and disease progression.

The multicenter PRO B trial found that weekly ePRO monitoring with alert-based nurse contact reduced fatigue vs usual care in metastatic breast cancer.

A secondary analysis of the phase 3 RxPONDER trial found that premenopausal women with low baseline AMH did not benefit from added chemotherapy vs endocrine therapy alone.

Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.

"New clinical evidence helps clarify which patients can benefit from radiation therapy,” said Daniel Chang, MD.

Phase 2 data show atezolizumab delivers durable responses in relapsed/refractory NK/T-cell lymphoma, with PD‑L1 markers helping predict benefit.

Cancer centers face rising outpatient demand; learn how smarter scheduling, better data, and AI-driven capacity planning ease flow, staffing strain, and complex therapy coordination.

Robert L. Ferris, MD, PhD, highlights how a virtual behavioral health program embedded in oncology care improved patients' QOL.

The iberdomide-daratumumab-dexamethasone regimen was approved based on superior MRD negativity rate vs standard of care in relapsed/refractory multiple myeloma.

Zipalertinib plus platinum-based chemotherapy significantly improved progression-free survival at a planned interim analysis of the phase 3 REZILIENT3 trial.

Registry data show bulky lymphoma drives different treatment choices and mixed survival effects, highlighting the need to standardize tumor bulk definitions.

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

The FDA has granted breakthrough device designation to Freenome's SimpleScreen Lung, an investigational blood-based test for high-risk lung cancer screening.

Three-year follow-up from the single-arm trial that led to talquetamab's approval showed durable progression-free survival and overall survival in heavily pretreated multiple myeloma.

Experts weigh response speed, survival and quality of life to choose first-line IO-TKI or dual immunotherapy for metastatic clear cell RCC.

The analysis builds on results from the phase 3 KEYNOTE-689 trial of perioperative pembrolizumab in HNSCC.

An analysis found that postprogression access to effective therapy was associated with smaller OS benefits in targeted therapy trials but not in immunotherapy trials.

The complete response letter did not cite any clinical issues regarding the NDA for 177Lu-edotreotide for GEP-NETs.

EIK1001, an agonist of TLR 7 and 8, is being investigated in first-line advanced melanoma in combination with pembrolizumab.

Nationwide data show CGP turnaround improves, but biopsy-to-order delays vary widely, slowing biomarker-driven care in lung and solid tumors.

During a live event, Sikander Ailawadhi, MD, and participants discussed how the route of CD38-antibody delivery, including a newly approved on-body injector, is shaping frontline regimen selection for transplant-ineligible multiple myeloma.

A guide to the biomarkers oncologists should test for in NSCLC, from established drivers like EGFR and ALK to newer targets such as MET exon 14 and HER2.

Ravi Salgia, MD, PhD, explains the goals of IMMUNO-BIOMAP, a phase 2 trial identifying biomarkers to predict immunotherapy response in NSCLC.

The FDA's Molecular and Clinical Genetics Panel will meet Sept. 23, 2026, to evaluate GRAIL's premarket approval application for the Galleri MCED test.

Liso-cel CAR T plus ibrutinib delivers deep remissions and high uMRD in relapsed CLL/SLL after multiple therapies, with manageable safety.

Benjamin Herzberg, MD, discusses unmet needs, immunotherapy sequencing, and referral timing in KRAS-mutant NSCLC.

A multimodal deep learning model trained in the NSABP B-42 trial and validated in TAILORx predicted late distant recurrence risk in HR-positive breast cancer.

Neoadjuvant inetetamab plus pyrotinib and chemotherapy achieved a 60.2% total pathologic complete response rate in the phase 2 neoPICD trial.